
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is poised for growth as the demand for radiation therapy continues to rise in the healthcare industry. The company's innovative technology, the CyberKnife, sets the standard for precise and effective radiation treatment for cancer and tumors. Despite a decrease in forecasted revenue and higher costs, the company's strong product and service offerings make it a sound investment for the future.
Bears say
Accuray is facing geopolitical headwinds and delays in shipping to certain regions, leading to decreased product and service revenue forecasts for the future. While the company has appointed a new executive and is working on expanding its service portfolio and distributor partnerships, the current uncertainty makes it difficult to predict when these initiatives will take effect. With a lack of progress in commercial execution and profitability metrics, coupled with a lengthy timeline for potential operational improvements, it is recommended to take a neutral stance on Accuray's stock.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares